Efficacy and Safety of Cladribine: Subcutaneous versus Intravenous Administration in Hairy Cell Leukemia Patients

Cladribine induces durable complete remission (CR) in approximately 85% of hairy cell leukemia (HCL) patients. In Egypt, cladribine is mainly used as IV continuous infusion at a dose of 0.1 mg/kg/day for 7 days and as SC bolus injection at a dose of 0.14 mg/kg/day for 5 days. We aimed to compare the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Mediterr J Hematol Infect Dis
Autors principals: Khorshid, Ola, Namour, Alfred Elias, El-Gammal, Mosaad M, Mahmoud, Tarek Yakout, Fortpied, Catherine, Abdel-Malek, Raafat, Ramadan, Safaa
Format: Artigo
Idioma:Inglês
Publicat: Università Cattolica del Sacro Cuore 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4621169/
https://ncbi.nlm.nih.gov/pubmed/26543527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4084/MJHID.2015.058
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars